Delving into the Latest Updates on Jinzhou Jiutai Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Mouth and Tooth Diseases

Cardiovascular Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4

Top 5 Target	Count

RARs(Retinoic acid receptors)	1
CYP51A1(Cytochrome P450 51)	1
Nav1.8(Sodium channel protein type X alpha subunit)	1

本试验旨在研究单次空腹和餐后口服锦州九泰药业有限责任公司研制、生产的泮托拉唑钠肠溶片（40 mg）的药代动力学特征；以Takeda GmbH生产的泮托拉唑钠肠溶片（潘妥洛克®，40 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

This study aimed to investigate the pharmacokinetic characteristics of pantoprazole sodium enteric-coated tablets (40 mg) developed and produced by Jinzhou Jiutai Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration; pantoprazole sodium enteric-coated tablets (Pantolok®, 40 mg) produced by Takeda GmbH was used as the reference preparation, and the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate the bioequivalence of the two preparations in humans.

Start Date14 Nov 2023

Sponsor / Collaborator

Jinzhou Jiutai Pharmaceutical Co. Ltd.

CTR20200497 / Completed

奥美拉唑肠溶胶囊在中国健康受试者中随机、开放、空腹状态下的生物等效性试验

[Translation] A randomized, open-label, fasting bioequivalence study of omeprazole enteric-coated capsules in Chinese healthy volunteers

主要目的：健康受试者空腹状态下，选择奥美拉唑肠溶胶囊与奥美拉唑肠溶胶囊（Losec®）进行空腹给药人体生物等效性试验，比较两种制剂在空腹给药条件下的生物等效性。次要目的：观察受试制剂奥美拉唑肠溶胶囊和参比制剂奥美拉唑肠溶胶囊（Losec®）在健康受试者中的安全性。

[Translation]

Primary objective: To conduct a human bioequivalence study of Omeprazole Enteric-coated Capsules and Omeprazole Enteric-coated Capsules (Losec®) in healthy subjects under fasting conditions, and to compare the bioequivalence of the two preparations under fasting conditions. Secondary objective: To observe the safety of the test preparation Omeprazole Enteric-coated Capsules and the reference preparation Omeprazole Enteric-coated Capsules (Losec®) in healthy subjects.

Start Date30 Mar 2020

Sponsor / Collaborator

Jinzhou Jiutai Pharmaceutical Co. Ltd.

CTR20192607 / Completed

奥美拉唑肠溶胶囊在中国健康受试者中随机、开放、餐后状态下的生物等效性试验

[Translation] A randomized, open-label, fed bioequivalence study of omeprazole enteric-coated capsules in Chinese healthy volunteers

主要目的：健康受试者餐后状态下，比较受试制剂奥美拉唑肠溶胶囊和参比制剂奥美拉唑肠溶胶囊（Losec®）在餐后给药条件下的生物等效性。次要目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary objective: To compare the bioequivalence of the test preparation Omeprazole Enteric-coated Capsules and the reference preparation Omeprazole Enteric-coated Capsules (Losec®) under postprandial administration conditions in healthy subjects. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date31 Dec 2019

Sponsor / Collaborator

Jinzhou Jiutai Pharmaceutical Co. Ltd.

100 Clinical Results associated with Jinzhou Jiutai Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Jinzhou Jiutai Pharmaceutical Co. Ltd.

Login to view more data

4

Literatures (Medical) associated with Jinzhou Jiutai Pharmaceutical Co. Ltd.

01 Mar 2019·Journal of Chemical Research

Synthesis, crystal structure and biological activity of 6-(3-chloropropoxy)-4-(2-fluorophenylamino)-7-methoxyquinazoline

Author: Zhao, Chen-kang ; Jin, Zheng-Sheng ; Li, Meng-Yao ; Zhao, Le-Jing ; Fu, Jia ; Shuai, Xiao-Min ; Ding, Hai-Guan ; Wang, Qing-Lin ; Cai, Zhi-Qiang ; Li, Shuai

The title compound, 6-(3-chloropropoxy)-4-(2-fluorophenylamino)-7-methoxyquinazoline, was synthesized by selective nucleophilic attack at C-1 of 1-bromo-3-chloropropane by the potassium salt of 4-(2-fluorophenylamino)-7-methoxyquinazolin-6-ol, which was prepared from 7-methoxy-4-oxo-3,4-dihydroquinazolin-6-yl acetate in three steps. The compound crystallized as an ethyl acetate complex (C20H21ClFN3O3, Mr = 405.85), and X-ray crystallography showed that the crystal belongs to the orthorhombic system, space group Pbca with a = 12.7407(4) Å, b = 14.0058(5) Å, c = 21.7726(7) Å, α = 90°, β = 90° and γ = 90°. The whole molecule is stacked into a three-dimensional structure via weak N–H…N hydrogen bonding between molecules. The compound acts as an effective inhibitor on the proliferation of a lung cancer cell line.

Shenyang Yaoke Daxue Xuebao

Chiral separation of miconazole using Chiralpak AD-H chiral column

Author: Yao, Xin-ning ; Liu, Yu-mei ; Guo, Xing-jie

This paper aims to establish a chiral separation method for miconazole using high performance liquid chromatog. (HPLC) on Chiralpak AD-H chiral column.The influences of the concentration of organic solvents and flow rate of the mobile phase, and temperature were examinedMiconazole could be separated optimally on Chiralpak AD-H chiral column using n-hexane-alc. (volume:volume= 90:10) as mobile phase at a flow rate of 0.6 mL/min^-1 and at 25°.The method is simple, quick, and reproducible.It can be used for enantioseparation of miconazole.

Scientific ReportsQ3 · CROSS-FIELD

Graphene Oxide Foam Supported Titanium(IV): Recoverable Heterogeneous Catalyst for Efficient, Selective Oxidation of Arylalkyl Sulfides to Sulfoxides Under Mild Conditions

Q3 · CROSS-FIELD

ArticleOA

Author: Ma, Wenxi ; Wang, Qinghe ; Tong, Qiaolin ; Wang, Jian ; Zhang, Meng ; Jiang, Hailun ; Liu, Yongxiang ; Yang, Huali ; Du, Guijie ; Cheng, Maosheng

AbstractAn efficient and environmentally friendly method was designed for the oxidation of sulfides to sulfoxides with a recyclable, carbon-skeleton-based heterogeneous catalyst developed by titanium sulfate [Ti(SO4)2] mineralization on the surface of graphene oxide foam [Ti(SO4)2@GOF] by using 30 wt% H2O2 as oxidant. Several different substituted sulfides were examined to explore the scope of substrates of the selective oxidation. The excellent reusability and durability of Ti(SO4)2@GOF was demonstrated by recycling experiments and the catalyst was further applied in the preparation of pantoprazole sodium in a one-pot process.

100 Deals associated with Jinzhou Jiutai Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Jinzhou Jiutai Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

4

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Metronidazole/Clotrimazole/Chlorhexidine Acetate ( CYP51A1 )	Bacterial Vaginosis More	Approved
Ethyl Aminobenzoate ( Nav1.8 )	Anesthesia More	Approved
Viaminati ( RARs )	Severe acne More	Approved
Carbocromen Hydrochloride	Angina Pectoris More	Approved
Trantinterol Hydrochloride ( β2-adrenergic receptor )	Asthma More	Pending